Sichuan Biokin Pharmaceutical (688506.SH): The first subject has been enrolled in the Phase III clinical trial for T-Bren in first-line HER2 mutated non-squamous non-small cell lung cancer.

Sichuan Biokin Pharmaceutical (688506.SH) announced that the company's independently developed innovative biopharmaceutical injection T-Bren (HER2ADC) has completed the enrollment of the first subject in a phase III clinical trial comparing it with the combination of pertuzumab plus platinum-based chemotherapy in first-line HER2-mutated advanced or metastatic non-squamous non-small cell lung cancer. T-Bren (BL-M07D1) is a novel ADC targeting HER2 with best-in-class potential, demonstrating significant anti-tumor efficacy in clinical trials. Recently, the clinical study of T-Bren compared to pertuzumab combined with platinum-based chemotherapy in first-line HER2-mutated advanced or metastatic non-squamous non-small cell lung cancer has entered the phase III clinical trial stage and completed the enrollment of the first subject. As of now, T-Bren is conducting 14 clinical trials both domestically and internationally, including 5 phase III trials, 1 phase II/III trial, 2 phase II trials, 3 phase I/II trials, and 3 phase I trials, covering indications such as first-line and second-line or higher HER2-positive breast cancer, postoperative adjuvant therapy for HER2-positive breast cancer, neoadjuvant therapy for HER2-positive breast cancer, HER2-low expression breast cancer, HER2-positive gastric or gastroesophageal junction adenocarcinoma, HER2-mutated non-squamous non-small cell lung cancer, as well as lung cancer, gastrointestinal tumors, urological tumors, and gynecological tumors, among others.